SouthernWorldwide.com – A diabetes drug, dapagliflozin, has shown promising potential in significantly reducing the risk of heart failure hospitalizations among a specific group of patients. This revelation comes from a new study published in Nature Medicine, offering a new avenue for preventive cardiovascular care.
The research focused on the SGLT2 inhibitor dapagliflozin, a medication primarily used for type 2 diabetes management. Scientists investigated its efficacy in preventing heart failure in individuals carrying rare genetic variants associated with cardiomyopathy, a progressive disease affecting the heart muscle.
By analyzing data from the extensive DECLARE-TIMI 58 trial, a team of researchers from Harvard Medical School, Mass General Brigham, and MIT examined the health records of over 12,000 adults. These participants all had type 2 diabetes and an elevated risk of cardiovascular issues.
Within this large cohort, approximately 121 individuals were identified as having inherited gene variants that predisposed them to developing cardiomyopathy. This genetic predisposition is a key factor in the study’s findings.
Following a median follow-up period of 4.2 years, the study revealed a notable difference in heart failure hospitalizations. Dapagliflozin was found to be significantly more effective in lowering these hospitalizations in individuals with the genetic variants compared to those without them.
While dapagliflozin provided benefits in reducing heart failure hospitalizations for both groups, the impact was substantially more pronounced in carriers of the genetic variant. The reduction in risk was approximately eight times greater for this specific subgroup.
Further details from the study highlighted the drug’s effectiveness. Among the 82% of genetic variant carriers who had no prior history of heart failure, 12.8% developed the condition in the placebo group. In stark contrast, no heart failure events were observed among carriers who received dapagliflozin.
Dr. Shinwan Kany, a co-lead author of the study and a visiting scientist at the Cardiovascular Research Center, Mass General Brigham Heart and Vascular Institute, and the Broad Institute, commented on the implications of these findings for preventive strategies. He expressed optimism about the potential to offer targeted therapies.
“Historically, identifying a genetic variant for cardiomyopathy mostly meant telling a patient they were at high risk and not having a specific preventive therapy to offer,” Dr. Kany stated in a press release. “These data show we do have tools to lower risk in these individuals.”
However, experts caution that these results, derived from an analysis of a larger randomized trial, require further validation. The limited sample size of carriers within the study also represents a limitation that warrants additional research.
Dr. Pamela Greene, who was not involved in the study, described the research as “important and provocative.” She highlighted the potential of SGLT2 inhibitors as a preventive measure.
The finding that participants without a history of heart failure who took dapagliflozin were less likely to develop the condition is particularly significant. Dr. Greene suggested this “raises the possibility that SGLT2 inhibitors may be especially useful as preventive therapy in genetically high-risk individuals.”
Despite the promising results, Dr. Greene advised a cautious approach. “This should be viewed as an exciting hypothesis-generating finding, not yet a practice-changing mandate for all patients with these genetic variants,” she cautioned.
She further elaborated on the established role of SGLT2 inhibitors. These medications are already considered “foundational” for their cardiovascular and kidney-protective benefits across a wide range of patients.
“They reduce heart failure hospitalization across a broad range of patients, including those with diabetes, chronic kidney disease and established heart failure,” Dr. Greene explained. “What this study adds is the possibility that genetic information may help identify a subgroup of people who derive especially large benefit from early treatment.”
The role of genetic testing in cardiology was also discussed. Freeman noted that genetic testing for cardiomyopathy is commonly employed for diagnosis, screening family members, and assessing risk stratification.
If future clinical trials corroborate these findings, cardiologists might eventually integrate genetic screening into their practice. This could enable them to identify high-risk patients, monitor them more closely, and initiate treatments like SGLT2 inhibitors proactively, even before heart failure symptoms manifest.
It is important to recognize that heart failure does not always emerge concurrently with noticeable symptoms. In some individuals, the underlying risk factors, particularly inherited genetic predispositions, may be present for years prior to the onset of clinical manifestations.
The field of preventive cardiology could be revolutionized by the ability to identify high-risk patients earlier. This proactive approach aims to intervene before symptoms such as shortness of breath, fluid retention, or the need for hospitalization become apparent.
Dr. Greene concluded by emphasizing the importance of personalized medical advice. “The decision to medicate should always be discussed with a clinician,” she advised. This is particularly crucial for individuals with a personal or family history of cardiovascular events.
